Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133302 | 0.88 | CYP1A2 (0.54) | ADORA1ADORA2AKMT2ACYP1A2 | |
| SCHEMBL6133337 | 0.86 | HSP90AA1 (0.48) | ADORA1ADORA2ACYP1A2CDK5CDK5R1 | |
| SCHEMBL6133777 | 0.86 | ADORA1 (0.41) | ADORA1ADORA2AKMT2ACYP1A2PDE3B | |
| SCHEMBL6133854 | 0.86 | LMNA (0.46) | ADORA1ADORA2AKMT2AMEN1LMNA | |
| SCHEMBL6134411 | 0.86 | LMNA (0.56) | ADORA1ADORA2AKMT2ACYP1A2PDE3B | |
| SCHEMBL6133787 | 0.84 | MAPKAPK2 (0.39) | ADORA1ADORA2AKMT2ACYP1A2CDK5 | |
| SCHEMBL6133724 | 0.83 | KMT2A (0.64) | ADORA1ADORA2AKMT2AMEN1LMNA | |
| SCHEMBL6133920 | 0.82 | ADORA1 (0.42) | ADORA1ADORA2AKMT2ACYP1A2PDE3B | |
| SCHEMBL6133937 | 0.81 | ADORA2A (0.39) | ADORA1ADORA2AKMT2ACYP1A2PDE3B | |
| SCHEMBL6134045 | 0.80 | RPS6KA3 (0.44) | ADORA1ADORA2AKMT2ACYP1A2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885KMT2A 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.